GRAIL
GRAL
Performance
About GRAIL
GRAIL is a healthcare company focused on detecting cancer earlier using blood-based multi-cancer early detection tests. It develops the Galleri Test and leverages next-generation sequencing, population-scale clinical studies, and advanced data analysis to identify cancer signals before symptoms appear. The company aims to alleviate the global burden of cancer with a mission-driven approach and operates with a focus on early detection across diverse populations in the United States and beyond.
Recent News
Clinical Trial Failures of 2026
Hims Adds Grail's Cancer Test Amid Questions About Widespread Use
Trial of Early Cancer Detection Test Misses Primary Endpoint
Invest in the Future of Cancer Diagnostics and Treatment
Toward Equitable Access to Cell and Gene Therapies: Rethinking Co-Payments
Top Medtech Executive Moves in 2026
Trial of Multi-Cancer Blood Test Among 142,000 NHS Patients Fails to Meet Main Aim
Grail Multi-Cancer Test Taps Into Hims & Hers Network
Grail Launches $950 Multi‑cancer Blood Test at ASCO, Sparking Debate over Cost and Efficacy
Isomorphic Labs Pulls $2.1B Series B Led By Thrive With MGX, Temasek, And UK Sovereign AI Fund: What The Capital Stack, IsoDDE Engine, And Novartis/Lilly/J&J Partnerships Mean For Drug Discovery
TOBY Gets FDA Breakthrough Device Designation for Urine-Based Multi-Cancer Test
Grail’s $824 Liquid Biopsy Test Sparks Debate Over Accuracy and Cost
S&P 500 Rises, Dow Gains 200 Points After Supreme Court Strikes Down Trump Emergency Tariffs: Live Updates
Grail Inc (GRAL) Q1 2026 Earnings Call Transcript
Quest Diagnostics Inc (DGX) Q1 2026 Earnings Call Transcript
Recent Deals
No recent deals for this company.